Regarding Systemic Lupus Erythematosus (SLE) Nephropathy
Statements (a) and (b) are correct: the histological class can change during disease course, and anti-dsDNA antibodies are routinely used to monitor lupus nephritis progression.
Analysis of Each Statement
a) Histological class may change during disease course: CORRECT
The EULAR/ERA-EDTA guidelines explicitly state that repeat renal biopsy may be used to "demonstrate change or progression in histological class" 1. This is recommended in cases of worsening disease, refractoriness to treatment, or at relapse. The guidelines recognize that lupus nephritis is a dynamic disease where histological patterns can evolve over time, necessitating repeat biopsies in selected clinical scenarios to guide therapeutic decisions 1.
b) Anti-dsDNA antibodies are used to monitor progression: CORRECT
The EULAR/ERA-EDTA guidelines explicitly recommend monitoring "serum anti-dsDNA antibody levels" at each visit for active lupus nephritis 1. The 2010 EULAR monitoring recommendations confirm that "changes in anti-double-stranded (ds) DNA antibody titres sometimes correlate with disease activity and active renal disease, and may be useful in monitoring disease activity" 2. While the diagnostic accuracy is modest (positive likelihood ratios 1.5-4.8), anti-dsDNA remains a standard monitoring parameter 1. Recent evidence shows that elevated anti-dsDNA levels can precede clinical lupus nephritis by years and that baseline anti-C1q and anti-dsDNA levels may predict treatment response 3, 4.
c) Survival on hemodialysis is lower compared to other primary diseases: INCORRECT
The evidence contradicts this statement. Patients with SLE on dialysis have excellent survival rates—89% at 5 years 5. The EULAR/ERA-EDTA guidelines state that "kidney transplant outcomes are similar to those in patients who developed kidney failure due to other types of kidney disease" 6. While the 2012 guidelines note that 10-30% of lupus nephritis patients progress to ESRD within 15 years 1, comparative studies support that SLE patients are good candidates for renal replacement therapy with outcomes comparable to other kidney diseases 1, 6.
d) Renal involvement at diagnosis occurs in only 10%: INCORRECT
This grossly underestimates the prevalence. The evidence indicates that 30-90% of SLE patients develop renal manifestations during disease course 7. While the exact percentage at initial diagnosis varies, the 10% figure is far too low. The guidelines emphasize that lupus nephritis is common and "has proven to be decisive for morbidity and mortality" 7.
e) Prevalence does not differ between sexes: INCORRECT
While the provided evidence doesn't explicitly address sex differences in lupus nephritis prevalence, this statement contradicts general medical knowledge. SLE itself has a strong female predominance (approximately 9:1 female-to-male ratio), and this sex disparity extends to lupus nephritis. The guidelines consistently refer to the "great majority of these patients are women in their childbearing years" 8, indicating clear sex differences in disease prevalence.
Clinical Implications
When managing lupus nephritis, clinicians should:
- Monitor anti-dsDNA antibodies regularly (every 2-4 weeks initially, then every 3-6 months) alongside complement levels, proteinuria, and renal function 1
- Consider repeat renal biopsy when there is treatment failure (proteinuria not decreasing by ≥50%, persistent proteinuria beyond 1 year, or worsening GFR) or at relapse to assess histological class changes 1
- Recognize that histological transformation occurs—a patient initially with Class III may progress to Class IV or develop chronicity features requiring treatment modification
- Counsel patients with ESRD that dialysis and transplantation outcomes are favorable, with survival rates comparable to other kidney diseases 6, 5